Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M14TIL: TIL vs Ipilimumab in Advanced Melanoma
NCT02278887Phase 3Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2014
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of GC101 TIL + pembrolizumab in melanoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression Free Survival at 3 years. Started Sep 2014; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02278887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278887.